A Study to Understand How the Study Medicine (PF-06823859) Works in People

Status Recruiting

Clinical Trial Summary

The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM. This study is seeking participants who: - Are 18 years of age or older. - Have active DM or active PM. - Are receiving a stable dose of 1 corticosteroid taken by mouth and/or 1 traditional immunosuppressant. - Note: Corticosteroids and immunosuppressants are medicines that help reduce inflammation and may signal to the immune system not to attack the body. Dermatomyositis (DM) is a rare disease that causes muscle inflammation that results in muscle weakness and low muscle stamina. Patients with DM have a characteristic skin rash. Polymyositis (PM) is a rare disease that involves mainly muscle inflammation resulting in muscle weakness, that can sometimes be painful. Patients with DM and PM may have trouble going up the steps, walking or getting to a standing position. Some of the participants will receive the study medicine (PF-06823859) and some will receive placebo (which is similar to study medicine but contains no medicine in it). The study medicine or placebo will be given as an intravenous (IV) infusion (directly into the veins), which takes about1 hour; every 4 weeks from Day 1 to Week 48 of the study. Both PF-06823859 and placebo and will be given at the study site. The study will compare the experiences of people receiving study medication to those of the people who do not. This will help to see if PF-06823859 is safe and effective. Participants will take part in this study for about 13 months. During this time, participants will have 16 study visits. These visits will be performed at the study site.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05895786
Study type	Interventional
Source	Pfizer
Contact	Pfizer CT.gov Call Center
Phone	1-800-718-1021
Email	ClinicalTrials.gov_Inquiries@pfizer.com
Status	Recruiting
Phase	Phase 3
Start date	May 20, 2023
Completion date	December 4, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06300983` - Effectiveness of a Psychoeducational Intervention on Myositis Patients' Quality of Life and Well-Being	N/A
Recruiting	`NCT05832034` - Add-on Intravenous Immunoglobulins in Early Myositis	Phase 2
Recruiting	`NCT05979441` - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy	Phase 3
Active, not recruiting	`NCT02468895` - MYOPROSP - a Prospective Cohort Study in Myositis
Recruiting	`NCT01501019` - Exercise in Sjogren, Myositis and Takayasu's Arteritis	N/A
Recruiting	`NCT05523167` - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.	Phase 2/Phase 3
Completed	`NCT03414086` - Predictor of Clinical Response to Acthar in Myositis
Not yet recruiting	`NCT01702870` - Diagnostic Accuracy of MR in Myositis	N/A
Terminated	`NCT03937856` - Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases	N/A
Completed	`NCT03440034` - Study of Pioglitazone in Sporadic Inclusion Body Myositis	Phase 1
Completed	`NCT00001331` - Genetic and Family Studies of Inherited Muscle Diseases	N/A
Not yet recruiting	`NCT06284954` - A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis	Phase 2
Terminated	`NCT04309227` - Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations	N/A
Completed	`NCT03059394` - Validation of Rehab Assessments in Myositis Patients	N/A
Completed	`NCT00106184` - Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)	Phase 2
Recruiting	`NCT04367350` - Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Active, not recruiting	`NCT01734369` - Environmental Risk Factors for Myositis in Military Personnel
Recruiting	`NCT02450396` - Pregnancy and Medically Assisted Conception in Rare Diseases
Recruiting	`NCT03912428` - Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Phase 1
Active, not recruiting	`NCT03215927` - Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms